Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
One type of coverall vs another type of coverall CI: confidence interval. · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Full‐face filtering masks vs no respiratory protection Asbestos exposure after doffing · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Full‐face filtering masks vs no respiratory protection Donning and doffing errors · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Full‐face filtering masks vs no respiratory protection Adverse effects · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Full‐face filtering masks vs no respiratory protection CI: confidence interval. · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Supplied air respirators vs no respiratory protection Reduction in exposure to asbestos · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | Moderate |
Supplied air respirators vs no respiratory protection Asbestos exposure after doffing · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Supplied air respirators vs no respiratory protection Donning and doffing errors · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Supplied air respirators vs no respiratory protection Adverse effects · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Off‐midline closure vs conventional midline closure Time to wound healing · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | no estimate extracted | 3 studies · 300 participants | Moderate |
Summary of findings table ‐ Off‐midline closure vs tension‐free midline closure Recurrence rate · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | RR 0.69 [0.3, 1.61] | 6 studies · 551 participants | Very low |
Summary of findings table ‐ Off‐midline closure vs tension‐free midline closure Wound infection · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | RR 0.44 [0.16, 1.17] | 6 studies · 559 participants | Very low |
Summary of findings table ‐ Off‐midline closure vs tension‐free midline closure Wound dehiscence · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | RR 0.82 [0.17, 3.84] | 3 studies · 250 participants | Very low |
Summary of findings table ‐ Off‐midline closure vs tension‐free midline closure Time to return to work · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | no estimate extracted | 1 study · 60 participants | Low |
Summary of findings table ‐ Off‐midline closure vs tension‐free midline closure Quality of life ‐ not reported · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Off‐midline closure (Karydakis flap) vs off‐midline closure (Limberg flap) Time to wound healing · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | no estimate extracted | 6 studies · 526 participants | Moderate |
Summary of findings table ‐ Off‐midline closure (Karydakis flap) vs off‐midline closure (Limberg flap) Proportion of wounds healed · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | RR 1.2 [0.77, 1.86] | 1 study · 30 participants | Low |
Summary of findings table ‐ Off‐midline closure (Karydakis flap) vs off‐midline closure (Limberg flap) Recurrence rate · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | RR 1.14 [0.61, 2.14] | 9 studies · 890 participants | Low |
Summary of findings table ‐ Off‐midline closure (Karydakis flap) vs off‐midline closure (Limberg flap) Wound infection · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | RR 1.55 [0.9, 2.68] | 8 studies · 869 participants | Low |
Summary of findings table ‐ Off‐midline closure (Karydakis flap) vs off‐midline closure (Limberg flap) Wound dehiscence · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | RR 1.2 [0.41, 3.5] | 7 studies · 776 participants | Low |
Summary of findings table ‐ Off‐midline closure vs conventional midline closure Proportion of wounds healed · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | RR 1.13 [0.92, 1.39] | 2 studies · 207 participants | Very low |
Summary of findings table ‐ Off‐midline closure (Karydakis flap) vs off‐midline closure (Limberg flap) Time to return to work · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | no estimate extracted | 6 studies · 541 participants | Low |
Summary of findings table ‐ Off‐midline closure (Karydakis flap) vs off‐midline closure (Limberg flap) Quality of life ‐ not reported · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Off‐midline closure vs conventional midline closure Recurrence rate · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | RR 0.22 [0.11, 0.45] | 13 studies · 1492 participants | Moderate |
Summary of findings table ‐ Off‐midline closure vs conventional midline closure Wound infection · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | RR 0.32 [0.22, 0.49] | 13 studies · 1568 participants | Moderate |
Summary of findings table ‐ Off‐midline closure vs conventional midline closure Wound dehiscence · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | RR 0.44 [0.27, 0.71] | 11 studies · 1389 participants | Low |
Summary of findings table ‐ Off‐midline closure vs conventional midline closure Time to return to work · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | no estimate extracted | 6 studies · 820 participants | Low |
Summary of findings table ‐ Off‐midline closure vs conventional midline closure Quality of life ‐ not reported · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Off‐midline closure vs tension‐free midline closure Time to wound healing · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | no estimate extracted | 1 study · 116 participants | Low |
Summary of findings table ‐ Off‐midline closure vs tension‐free midline closure Proportion of wounds healed · pilonidal sinus Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus (2024) · Cochrane | RR 1.24 [1.06, 1.46] | 1 study · 115 participants | Low |
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment All‐cause mortality – at 28 to 30 days, or in‐hospital · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane | RR 0.84 [0.49, 1.46] | 11 studies · 3459 participants | Very low |
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Progression to invasive mechanical ventilation · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane | RR 0.86 [0.68, 1.09] | 8 studies · 1383 participants | Very low |
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Need for admission to hospital (if ambulatory) · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane | RR 1.04 [0.44, 2.46] | 4 studies · 670 participants | Low |
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Time to clinical improvement (defined as time to a 2‐point reduction in patients’ admission status on WHO’s ordinal scale) · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane | HR 1.13 [0.69, 1.83] | 4 studies · 721 participants | Very low |
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Progression to oxygen therapy · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane | RR 1.2 [0.83, 1.75] | 2 studies · 543 participants | Low |
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment All adverse events · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane | RR 1.27 [1.05, 1.54] | 18 studies · 4699 participants | Low |
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Serious adverse events attributable to the drug · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane | RR 1.04 [0.76, 1.42] | 12 studies · 3317 participants | Low |
Summary of findings table ‐ Vitamin A supplements vs placebo Incidence of acute URTIs during the study period (the number of acute URTIs over a period of time) · children up to the age of 7 at risk of upper respiratory tract infection Oral vitamin A supplements to prevent acute upper respiratory tract infections in children up to seven years… (2024) · Cochrane | RR 1 [0.92, 1.09] | 3 studies · 22668 participants | Low |
Summary of findings table ‐ Vitamin A supplements vs placebo Incidence of acute URTIs during the study period (proportion of participants with an acute URTI) · children up to the age of 7 at risk of upper respiratory tract infection Oral vitamin A supplements to prevent acute upper respiratory tract infections in children up to seven years… (2024) · Cochrane | no estimate extracted | 2 studies · 15535 participants | Low |
Summary of findings table ‐ Vitamin A supplements vs placebo Adverse events · children up to the age of 7 at risk of upper respiratory tract infection Oral vitamin A supplements to prevent acute upper respiratory tract infections in children up to seven years… (2024) · Cochrane | no estimate extracted | 1 study · 116 participants | Very low |
Summary of findings table ‐ Vitamin A supplements vs placebo Severity of subjective symptoms (mean duration of acute URTI) · children up to the age of 7 at risk of upper respiratory tract infection Oral vitamin A supplements to prevent acute upper respiratory tract infections in children up to seven years… (2024) · Cochrane | no estimate extracted | 2 studies · 290 participants | Very low |
Summary of findings table ‐ Vitamin A supplements vs placebo Time to occurrence of acute URTI ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection Oral vitamin A supplements to prevent acute upper respiratory tract infections in children up to seven years… (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Vitamin A supplements vs placebo Number of cases with complications ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection Oral vitamin A supplements to prevent acute upper respiratory tract infections in children up to seven years… (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Vitamin A supplements vs placebo Rate of hospitalisation ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection Oral vitamin A supplements to prevent acute upper respiratory tract infections in children up to seven years… (2024) · Cochrane | no estimate extracted | NR | No studies |
Dietary interventions vs control BMI short‐term (12 weeks from baseline to < 9 months) · children aged 5 to 11 years Interventions to prevent obesity in children aged 5 to 11 years old (2024) · Cochrane | no estimate extracted | 5 studies · 2107 participants | Low |
Activity interventions vs control BMI long‐term (> 15 months) · children aged 5 to 11 years Interventions to prevent obesity in children aged 5 to 11 years old (2024) · Cochrane | no estimate extracted | 8 studies · 8302 participants | Low |
Activity interventions vs control zBMI short‐term (12 weeks from baseline to < 9 months) · children aged 5 to 11 years Interventions to prevent obesity in children aged 5 to 11 years old (2024) · Cochrane | no estimate extracted | 6 studies · 3580 participants | Low |
Activity interventions vs control zBMI medium‐term (9 months to < 15 months) · children aged 5 to 11 years Interventions to prevent obesity in children aged 5 to 11 years old (2024) · Cochrane | no estimate extracted | 13 studies · 20600 participants | Moderate |
Activity interventions vs control zBMI long‐term (> 15 months) · children aged 5 to 11 years Interventions to prevent obesity in children aged 5 to 11 years old (2024) · Cochrane | no estimate extracted | 6 studies · 6940 participants | Low |
Activity interventions vs control Serious adverse events · children aged 5 to 11 years Interventions to prevent obesity in children aged 5 to 11 years old (2024) · Cochrane | no estimate extracted | 11 studies · 21278 participants | Low |